435 related articles for article (PubMed ID: 32385714)
1. CDK7 inhibitors as anticancer drugs.
Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Liang H; Du J; Elhassan RM; Hou X; Fang H
Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
[No Abstract] [Full Text] [Related]
3. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
Fisher RP
Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
[TBL] [Abstract][Full Text] [Related]
4. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for CDK7 activation by MAT1 and Cyclin H.
Peissert S; Schlosser A; Kendel R; Kuper J; Kisker C
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26739-26748. PubMed ID: 33055219
[TBL] [Abstract][Full Text] [Related]
8. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
Diab S; Yu M; Wang S
J Med Chem; 2020 Jul; 63(14):7458-7474. PubMed ID: 32150405
[TBL] [Abstract][Full Text] [Related]
9. TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters.
Webb BM; Bryson BL; Williams-Medina E; Bobbitt JR; Seachrist DD; Anstine LJ; Keri RA
J Biol Chem; 2021 Oct; 297(4):101162. PubMed ID: 34481843
[TBL] [Abstract][Full Text] [Related]
10. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
11. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?
Lolli G; Johnson LN
Cell Cycle; 2005 Apr; 4(4):572-7. PubMed ID: 15876871
[TBL] [Abstract][Full Text] [Related]
12. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
13. Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.
Patel H; Abduljabbar R; Lai CF; Periyasamy M; Harrod A; Gemma C; Steel JH; Patel N; Busonero C; Jerjees D; Remenyi J; Smith S; Gomm JJ; Magnani L; Győrffy B; Jones LJ; Fuller-Pace F; Shousha S; Buluwela L; Rakha EA; Ellis IO; Coombes RC; Ali S
Clin Cancer Res; 2016 Dec; 22(23):5929-5938. PubMed ID: 27301701
[TBL] [Abstract][Full Text] [Related]
14. Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts?
Fesquet D; Morin N; Doree M; Devault A
Oncogene; 1997 Sep; 15(11):1303-7. PubMed ID: 9315098
[TBL] [Abstract][Full Text] [Related]
15. The cryoelectron microscopy structure of the human CDK-activating kinase.
Greber BJ; Perez-Bertoldi JM; Lim K; Iavarone AT; Toso DB; Nogales E
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22849-22857. PubMed ID: 32855301
[TBL] [Abstract][Full Text] [Related]
16. ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942.
Sava GP; Fan H; Fisher RA; Lusvarghi S; Pancholi S; Ambudkar SV; Martin LA; Charles Coombes R; Buluwela L; Ali S
Oncogene; 2020 Jan; 39(3):651-663. PubMed ID: 31530935
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CDK7 substrate specificity by MAT1 and TFIIH.
Yankulov KY; Bentley DL
EMBO J; 1997 Apr; 16(7):1638-46. PubMed ID: 9130709
[TBL] [Abstract][Full Text] [Related]
18. 2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942.
Greber BJ; Remis J; Ali S; Nogales E
Biophys J; 2021 Feb; 120(4):677-686. PubMed ID: 33476598
[TBL] [Abstract][Full Text] [Related]
19. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
20. Modulation of TFIIH-associated kinase activity by complex formation and its relationship with CTD phosphorylation of RNA polymerase II.
Watanabe Y; Fujimoto H; Watanabe T; Maekawa T; Masutani C; Hanaoka F; Ohkuma Y
Genes Cells; 2000 May; 5(5):407-23. PubMed ID: 10886368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
